Eli Lilly has become the first pharma group to reach a value of more than $1 trillion, joining a select group populated mainly by tech giants.
Makary pushes for IRB reforms to catch China’s speedy trial starts
The process by which institutional review boards oversee clinical trials needs reforms that are “big and different” so that the US can keep pace with


